|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
RED CELLS
From the Department of Laboratory Medicine, Children's
Hospital Boston, and the Department of Pathology, Brigham and Women's
Hospital, Boston, MA.
It has recently been shown that the Gardos channel activity of
mouse erythrocytes can be modified by endothelins, suggesting a
functional linkage between endothelin receptors and the Gardos channel.
Using 86Rubidium (86Rb) influx, effects
were estimated of proinflammatory molecules such as platelet activator
factor (PAF), endothelin-1 (ET-1), interleukin-10 (IL-10), and
regulated on activation normal T cells expressed and secreted (RANTES)
on the Gardos channel activity in human normal and sickle red cells. It
was found that PAF (EC50: 15 ± 7 nM), RANTES
(EC50, 9 ± 6 ng/mL [1.2 ± 0.8 nM]), IL-10
(EC50, 11 ± 8 ng/mL [204 ± 148 nM]), and ET-1
(EC50, 123 ± 34 nM) induce a significant increase in
Gardos channel activity Sickle cell disease is characterized by chronic
hemolytic anemia, frequent infection, and occlusion of the
microcirculation that result in organ damage and painful episodes.
Plasma levels of several proinflammatory and adhesive cytokines have
been shown to be increased in sickle cell disease.1-5
However, little is known about their contribution to its pathogenesis,
though a relationship between adhesiveness of the sickle cells and the
clinical state of the patients has been observed.6 It has
been postulated that factors that activate vascular endothelium may
enhance the attachment of young reticulocytes and sickle cells to the
endothelium and may cause delays in the passage of red cells through
the microcirculation.7,8 The prolonged microvascular
transit time of sickle red cells may then provide the necessary time
for hemoglobin polymerization, cell sickling, and vaso-occlusion to
occur.9
Red cell sickling and adhesion are favored by cellular dehydration,
which increases the rate of hemoglobin polymerization and cell
sickling.10 Previous data have shown that the dehydration of sickle erythrocytes mediated by the Ca++-activated
K+ channel (Gardos channel) can be activated in vitro by
oxygenation-deoxygenation cycles.11 Blockade of the
Gardos channel by clotrimazole induces a reduction in red cell
dehydration in vivo and in vitro.12,13 We postulated that
activators of the Gardos channel might favor the formation of dense
sickle cells and cell entrapment in the microvasculature. The
arachidonic acid derivative prostaglandin E2 has been shown
to activate the erythrocyte Gardos channel in healthy subjects and to
alter size and membrane deformability.14 We recently found
that endothelin-1 (ET-1) can also induce activation of the Gardos
channel through a protein kinase C (PKC)-dependent mechanism in mouse
erythrocytes.15 Here we describe the effect of various
cytokines on the Gardos channel activity and their relationship with
cell volume regulation in normal and sickle erythrocytes. In addition,
we provide evidence that the ET-1 receptor subtype B (ETB)
gene is transcribed in the erythroid precursors. The data
suggest that activation of the Gardos channel might be functionally
coupled to receptors such as C-X-C (PAF), C-C (RANTES), and ET receptor
subtype B-1.15-17
Drugs and chemicals
Erythrocyte preparation
Measurement of 86Rb influx Freshly washed erythrocytes were suspended at 2% hematocrit in an influx medium containing 145 mM NaCl, 2 mM KCl, 0.15 mM MgCl2, 0.1 mM ouabain, 10 mM Tris-MOPS, pH 7.4 (22°C), 10 µM bumetanide, and 10 µCi /mL (0.37 MBq/mL) 86Rb in the presence or absence of the specified peptide agents. Preincubations with cytokines or chemokines were carried out for 20 minutes at 37°C in an isotonic sodium medium. The same concentrations of active peptides were added to the influx medium. Free ionic Ca++ in the influx medium was buffered between 0 and 7 µM with 1 mM EGTA or citrate buffer.18 Ca++ concentration was calculated using the dissociation constants for EGTA or citrate and correcting for ionic strength at pH 7.4 and the presence of 0.15 mM MgCl2. At time 0 minute, A23187 ionophore (5 µM) was added, and aliquots at 2 and 5 minutes were removed and immediately spun down through 0.8 mL cold medium containing 5 mM EGTA buffer and an underlying cushion of n-butyl phthalate. Supernatants were aspirated, and the tube tip containing the cell pellet was cut off. Erythrocyte-associated radioactivity was counted in a gamma counter (model 41600 HE; Isomedic ICN Biomedicals, Costa Mesa, CA). K+ uptake was linear up to 5 minutes, and fluxes were calculated from linear regression slopes.15ET-1 binding assays Two different assays were used to characterize the ET-1 binding sites in intact erythrocytes, one to compare with the flux experiment and the other to look for high-affinity binding sites. In the first assay, erythrocytes were washed with CWS and were suspended at 1% hematocrit (approximately 4 × 106 cells) for 15 minutes at room temperature in a binding solution containing 145 mM NaCl, 2 mM KCl, 0.15 mM MgCl2, 10 mM Tris-MOPS, pH 7.4, 0.02 mg/mL bovine serum albumin (BSA), and 100 to 500 nM [125I]-ET-1 in the absence or presence of 10 µM unlabeled ET-1, as described in the figure legends. At specific time points, aliquots of 0.1 mL were passed through Microfiber GF/B filters (Whatman International, Maidstone, England) and were washed with 5 vol binding medium at room temperature. In the second assay, binding experiments performed at 4°C the erythrocytes were washed with CWS and were suspended at 10% hematocrit for 1 hour at 4°C in a binding solution containing 145 mM NaCl, 2 mM KCl, 0.15 mM MgCl2, 10 mM Tris-MOPS, pH 8.0 (4°C), and 0.1 mg/mL BSA. Cells were centrifuged and added to a final concentration of 1 × 106 cell/mL in binding medium without BSA, containing [125I]-ET-1 in the absence or presence of unlabeled ET-1. Cell suspensions were incubated up to 1 hour at 4°C unless otherwise stated. At specific time points, aliquots of 0.25 mL were passed through Microfiber GF/B filters (Whatman International) and were washed with 5 vol binding medium at 4°C. In both protocols the filters were presoaked for 1 hour at room temperature in BSA-binding solution (0.1%). Cell radioactivity-containing filters were counted in a gamma counter. All linear or nonlinear curve fittings were performed as described in the figure legends using Sigmaplot (version 5; SPSS Science, Chicago, IL), unless otherwise stated.Cyclic oxygenation-deoxygenation and erythrocyte volume regulation experiments Red cells were washed 3 time with CWS and were incubated in a plasmalike buffer containing 145 mM NaCl, 2 mM KCl, 25 mM NaHCO3, 10 mM glucose, 0.06 mM adenosine, 0.04 mM inosine, 0.15 mM MgCl2, and 2 mM CaCl2 with and without the specified compound for 5 hours (30% hematocrit) under a 10-minute oxygenation-deoxygenation cycle. Each cycle provided 3 minutes of 15% O2/5% CO2 balanced with N2 and 7 minutes of 5% CO2 balanced with N2 gas. The gases were humidified through bubbling in a column containing an isotonic saline solution at 37°C. Cell suspension was then transferred to an ice bath, and the medium was replaced by a Tris-MOPS-buffered isotonic saline. Density distribution curves were obtained using phthalate esters in microhematocrit tubes.12 Briefly, phthalate solutions were prepared to give a range of densities between 1.08 and 1.11 g/mL. Hematocrit tubes were filled with 30 µL cell suspension and 10 µL different phthalate solutions.13 Tubes were centrifuged at 12 200 rpm for 10 minutes at room temperature. The amount of denser cells was calculated from the amount of denser cells (lower layer) over the total amount of cells and was expressed as a percentage.Preparation of RNA Human blood was collected in tubes containing acid citrate dextrose solution. Total reticulocyte RNA was isolated by the ammonium chloride lysis technique.19 RNA was prepared from erythroid cultures. Two-stage erythroid culture derived from normal human peripheral blood was set up as described by Fibach et al.20,21 Cells were harvested and counted between culture days 10 and 19. In addition, RNA was prepared from primary culture of human lung microvascular endothelial cells (Clonetics, San Diego, CA) and smooth muscle cells by lysis in Trizol (Life Technologies, Rockville, MD), followed by DNase treatment and purification using the RNeasy Clean-Up protocol (Qiagen, Valencia, CA).Reverse transcription-polymerase chain reaction amplification and DNA sequencing RNA was reverse transcribed using random hexamers (Promega, Fitchburg Center, WI), and the cDNA was polymerase chain reaction (PCR)-amplified using primers HER-A1 (5'-GCAATGGCTCAATGCACAAC-3') and HER-A2 (5'-TAAGACGCAGAGGTTGAGG-3') specific for the ET-1 receptor subtype A cDNA and using primers HER-B1 (5'-GGTCTCTGTGGTTCTGGCTG-3') and HER-B2 5'-TAAAGCAATCTGCATGCCAC-3') specific for the ET-1 receptor subtype B cDNA. PCR conditions were 35 cycles for 10 seconds at 94°C, 30 seconds at 65°C, and 10 seconds at 74°C. Expected sizes of PCR products for ETA and ETB were 357 bp and 253 bp, respectively. The PCR product obtained from erythroid precursors was sequenced using the ABI 377 automated sequencer.
Functional characterization of sickle erythrocyte Gardos channel Activation of the K+ influx by cellular Ca++ was studied by clamping intracellular Ca++ at desired values with the Ca++ ionophore A23187.22 Figure 1 shows the dependence of ChTX-sensitive K+ influx on extracellular free Ca++ in normal and sickle erythrocytes. In normal erythrocytes, K+ influx increased rapidly and saturated approximately 0.6 mmol/L cells × minute, when Ca++ was increased to 4 µM. Nonlinear fitting of the experimental points for a sigmoid function gave a Vmax of 0.71 ± 0.14 mmol/1013 cells per minute (n = 10). ChTX-sensitive flux kinetic analysis showed a constant affinity for Ca++ (K0.5) of 1.21 ± 0.66 µM (n = 3). Similar experiments, in sickle erythrocytes, revealed that the Vmax of the system was significantly higher than in normal erythrocytes (from 0.71 to 1.49 ± 0.24 mmol/1013 cells per minute, n = 3, P < .05). In addition, sickle erythrocytes showed a significantly lower affinity constant for Ca++ (from 1.21 to 0.46 ± 0.3 µM, n = 3, P < .045). Thus, in sickle erythrocytes, activation of the Gardos channel occurs at a much lower intracellular Ca++ concentration than in normal cells. This difference in the Ca++ activation set point of the channel between normal and sickle erythrocytes might imply that smaller changes in cytosolic Ca++ could trigger the activation of the K+ channel in sickle erythrocytes. These results are in accord with previous studies in which differences between sickle and normal red cells were found in relation to the Ca++ affinity constant for the human channel measuring K+ efflux.18
Effects of cytokines on Gardos channel activity in erythrocytes RANTES, PAF, IL-10, and ET-1 have been shown to increase cytosolic Ca++ in a variety of mammalian cells.23-25 A promiscuous chemokine receptor that binds C-X-C- and C-C-type chemokines with high affinity has been shown in erythrocytes.17,26-29 We tested the effects of RANTES (C-C) and other cytokines that mediate their action through other specific receptors such as ET-1, IL-10, and PAF on Gardos channel activity in normal erythrocytes in the presence of 5 µM A23187 and 1 µM ionized extracellular Ca++. As shown in Figure 2, all 4 cytokines significantly increased channel activity in normal erythrocytes. To determine the specificity of these effects on the Gardos channel by the chemokine receptor, we performed similar experiments using erythrocytes that lacked the Duffy antigen receptor (Figure 2). In Duffy-negative erythrocytes, ET-1 and IL-10 were able to stimulate Gardos activity significantly (n = 3, P < .03). As expected, the presence of RANTES and PAF did not further induce activation of the Gardos channel in Duffy-negative cells.
Kinetic analysis of the Gardos channel activity in the presence of
these cytokines indicated that IL-10, RANTES, and PAF factors modified
the constant affinity for intracellular Ca++ and increased
the apparent maximal velocity (Vmax) of the channel transport (Table 1). A dose-response
curve of the effects of these peptides on channel activity indicated a
50% stimulatory concentration (EC50) of channel activity
at the nanomolar level, suggesting the specificity of channel
activation by these peptides (Table 1). Because intracellular
Ca++ was clamped at a specific concentration, a change in
free intracellular Ca++ could not account for Gardos
channel activation.
ET-1 alters the kinetic parameters of the Gardos channel in human erythrocytes We have shown that ET-1 activates the Gardos channel of mouse erythrocytes.15 Because ET-1 has been found consistently elevated in the plasma of patients with steady state sickle cell disease, we measured ChTX-sensitive K+ influx in the presence and absence of 300 nM ET-1 in normal and sickle erythrocytes in the absence of Ca++ ionophore A23187 (Figure 3). The medium contained 1.5 mM Ca++. In normal erythrocytes, ChTX-sensitive K+ influx tripled in cells incubated with 300 nM ET-1. In sickle erythrocytes, we also observed a 38% increase after 300 nM ET-1 incubation (Figure 3). These data, obtained in the absence of any Ca++ ionophore, suggest that ET-1 might induce changes in red cell volume by increasing K+ flux in vivo.
To further characterize ET-1 effects on human red blood cells, we
studied the specific effect of ET-1 on the kinetic properties of the
Gardos channel. The dependence of the channel activity on free
Ca++ was determined in normal and sickle erythrocytes
pretreated with (or without) 500 nM ET-1 (Table
2). Vmax of the channel
increased 2-fold in normal erythrocytes pretreated with ET-1
(P < .03). The increase in the Vmax of the
Gardos channel by ET-1 suggested that ET-1 receptor activation
increases either the open time of active units or the number of active
channels by recruiting quiescent channels. Ca++ dependence
of ET-1-induced ChTX-sensitive K+ influx shows that the
K0.5 for Ca++ decreases from 1.2 ± 0.7 to
0.6 ± 0.1 µM (P < .03). This suggests that the
activation of endothelin receptors in normal erythrocytes regulates the
Ca++ affinity site or an undefined
Ca++-dependent regulatory protein closely related to the
Gardos channel. In sickle erythrocytes, Vmax was almost
doubled in the presence of ET-1 (from 1.5 ± 0.2 to 2.15 ± 0.01
mmol/1013 cells per minute; P < .045), and
K0.5 was significantly reduced from 0.5 ± 0.03 to
0.21 ± 0.01 µM (P < .03). A dose-response curve of
ET-1 effects on the channel activity indicated an EC50 of
123 ± 34 nM in normal human erythrocytes.
ET-1 receptor in normal and sickle erythrocytes We previously demonstrated the presence of ET receptors in mouse erythrocytes.15 To test whether ET-1 specifically binds to an endothelin receptor in human erythrocytes, we measured [125I]-ET-1 binding to intact normal erythrocytes. Specific [125I]-ET-1 binding reached a plateau in 30 minutes at room temperature (data not shown). Specific binding to erythrocytes was a saturable process consistent with a specific receptor interaction. Specific binding was similar between sickle and normal erythrocytes (Figure 4). To evaluate the specific characteristic of the ET-1 receptor in normal and sickle erythrocytes, we measured the specific binding of radiolabeled ET-1 as a function of [125I]-ET-1 concentration in normal and sickle erythrocytes at room temperature. Scatchard analysis revealed the presence of an affinity binding site with an apparent dissociation constant (Kd) of 128 ± 73 nM and a maximal binding capacity (Bmax) of 238 ± 53 sites/cell for normal red blood cells. In sickle cells, similar values were obtained (Kd = 244 ± 105 nM, Bmax = 336 ± 78 sites/cell).
Experiments performed at 4°C indicated that the specific [125I]-ET-1 binding reached a plateau in 60 to 80 minutes at 4°C (data not shown). Under these experimental conditions, specific binding was also similar between sickle and normal erythrocytes. However, Scatchard analysis revealed the presence of a class of higher affinity-binding sites with an apparent Kd of 47 ± 8 pM and a Bmax of 277 ± 23 sites/cell for normal erythrocytes (not shown). In sickle cells, similar values were obtained (Kd = 48 ± 10 pM, Bmax = 307 ± 56 sites per cell; not shown). Although we were only able to detect one class of binding site under experimental conditions that resembled the ET-1-stimulated Gardos channel activity in human erythrocytes, the possibility of 2 ET-1-binding sites, as we described previously in mouse erythrocytes, 15 should not be eliminated. ETB receptor antagonist inhibits ET-1-induced Gardos activity in human erythrocytes To test whether ET-1 action on the Gardos channel was mediated by an ETB receptor as seen in mouse erythrocytes, we measured the effect of the ET receptor antagonists, BQ123 and BQ788, on Gardos channel activity in normal and sickle erythrocytes (Figure 5). Preincubation of erythrocytes with ET-1 (500 nM) was performed in the presence or absence of BQ788 or BQ123 (1 µM) for 20 minutes at 37°C. BQ788, a specific and selective ETB antagonist, significantly (85%-90%) decreased ET-1-induced activation of the Gardos channel in both cell types. BQ123, a specific antagonist of ETA receptors, did not significantly decrease ET-1-induced Gardos activity.
ETB mRNA is detected in erythroid precursors PCR amplification of reverse-transcribed RNA isolated from erythroid precursors of healthy subjects yielded a product corresponding to ETB. In control experiments, we amplified the ETA from smooth muscle cell cDNA and the ETB from endothelial cell cDNA. No PCR product was amplified from erythroid precursor cDNA using primers specific for ETA, whereas a band of the expected size, 357 bp, was obtained from smooth muscle cell cDNA. A PCR product of 253 bp, corresponding to ETB, was PCR amplified from the erythroid precursor cDNA and from endothelial cells. DNA sequencing of the PCR product obtained with primers HER-B1 and HER-B2 confirmed that it corresponded to mRNA encoding human ETB receptor.Protein kinase C effects on Gardos channel in human erythrocytes The role of PKC as a regulator of the Gardos channel has been suggested in human sickle and mouse erythrocytes.15,30 To evaluate the effect of PKC on Gardos channel activation, we measured Gardos channel activity in cells pretreated with different inhibitors of PKC in human erythrocytes (Figure 6). Staurosporin and chelerythrine are potent inhibitors of PKC by competitive inhibition of adenosine triphosphate binding.31 Calphostin C is a potent, selective PKC inhibitor that affects the phorbol-ester binding site. All 3 inhibitors significantly decreased the Vmax of the channel staurosporin from 0.75 ± 0.2 to 0.41 ± 0.1 mM cell per
minute (P < .05), calphostin C to 0.13 ± 0.01 mM cell
per minute (P < .05), and chelerythrine to 0.11 ± 0.02
mM cell per minute (P < .05). Furthermore, calphostin C
and chelerythrine were able to significantly increase the affinity constant for Ca++ (K0.5) from 0.9 ± 0.1 µM
to 1.3 ± 0.1 µM (n = 3, P < .05). These data
indicate that Gardos channel activity is modulated by PKC in human
erythrocytes.
ET-1-induced dense cell formation in sickle erythrocytes It has been shown that cycles of deoxygenation and oxygenation induce dense cell formation in sickle erythrocytes.11 The cyclic oxygenation-deoxygenation protocol used here also induces a significant change in the density profile, as shown in Figure 7. Analysis of the baseline density profile indicates a median density (D50) of 1.086 g/mL. This value was significantly increased up to 1.092 ± 0.0003 (n = 4, P < .05) after 5 hours of deoxygenation-oxygenation cycles in a plasmalike buffer containing 1.5 mM CaCl2. Under similar conditions, the effect of 300 nM ET-1 was tested (Figure 7). ET-1 shifted the phthalate density profile curve to the right, increasing further the D50 up to 1.098 (n = 3, P < .05). These data suggest that ET-1 enhances dense cell formation mediated by the Gardos channel.
To evaluate the effect of the chemokine receptor on cell dense
formation, deoxy-oxygenation experiments were performed in normal and
Duffy-negative erythrocytes. The cytokine effects on density of the red
cell after 5 hours of deoxygenation and oxygenation cycles were
determined using 1.1 g/mL phthalate oil. As Figure 8 shows, normal erythrocyte density
increases significantly (n = 3, P < .05) in the
presence of 20 ng/mL (370 nM) IL-10, 200 nM PAF, and 20 ng/mL (2.6 nM)
RANTES and of 500 nM ET-1 compared with the control value under similar
conditions. In Duffy-negative erythrocytes, similar results were found
with ET-1 and IL-10 but not with RANTES, in accordance with the absence
of this receptor. PAF increased significantly (n = 3,
P < .05) the amount of dense cells, which suggests that
PAF actions are not mediated by chemokine receptor.
Elevated levels of cytokines such as ET-1,4,5 IL-8,2 and PAF1,32 have been found in the plasma of patients with sickle cell disease. It is believed that they play an important role in the adhesion of sickle erythrocytes to the endothelium and in the pathogenesis of vaso-occlusive episodes.1,3 Based on our previous finding that ET-1 induced activation of the Gardos channel in mouse red cells,15 we speculated that cytokines might promote vaso-occlusion and sickling by inducing sickle erythrocyte dehydration through the activation of the Gardos channel. We have shown in this report that several cytokines can activate the Gardos channel in human erythrocytes (Tables 1, 2). The physiological role of the chemokine receptor in red cells was unknown, but clearance of chemokines from the circulation has been proposed.28 This receptor is identical to the Duffy antigen, which also functions as a receptor for Plasmodium vivax.33 We have presented evidence that this receptor might also be involved in red cell volume regulation because we found that RANTES and PAF significantly modulated the Vmax and the Kd for intracellular Ca++ of the Gardos channel. These findings are in agreement with previous reports that activation of the chemokine receptor induced an increase in the Ca++-activated K+ current in human primary macrophage cultures.34 In addition, the absence of Gardos channel stimulation by RANTES in Duffy-negative red cells suggested a specific interaction of this receptor with the Gardos channel. Previous studies have indicated that the activation of ET-1 receptors
mobilizes intracellular Ca++ stores in nonerythroid
cells,35-38 but whether cytosolic Ca++ in red
cells is affected by ET-1 is unknown. Other intracellular signaling
mechanisms that mediate ET-1 actions include phospholipase C,
diacylglycerol, and PKC.39 Human erythrocytes express only 2 isoforms of PKC, Sickle erythrocytes have been shown to interact with vascular endothelial cells, stimulating the release of ET-1 and regulating the expression of the ET-1 gene in culture endothelial cells.42 However, we do not know whether increased plasma levels of ET-1 can modulate the Gardos channel in vivo. Although the concentration of ET-1 necessary to stimulate the Gardos channel in vitro exceeds the levels documented in patient plasma during painful crises, it is likely that local levels of ET-1 are higher than those measured systemically. The activation of the Gardos channel by ET-1 in the absence of A23187 (Figure 3) could suggest the coupling of the Gardos channel to the ET-1 receptor in vivo. This is in agreement with ET-1 significantly changing the dehydration state of erythrocytes when the cells are exposed to oxygenation-deoxygenation cycles, as occurs in physiological conditions (Figure 7). The role of ET-1 in sickle cell dehydration is under further investigation in the transgenic sickle mouse model using ET-1 receptor antagonists. Despite multiple attempts, we did not succeed in amplifying endothelin
receptors from reticulocyte cDNA. This is surprising because we
previously amplified, without difficulty, reticulocyte cDNA
corresponding to major proteins of the membrane skeleton, including Because some of these cytokines interact with their specific receptors, it is possible that the Gardos channel and these receptors are functionally coupled in human erythrocytes by intracellular enzymatic activation pathways. Therefore, these findings might offer potential new therapeutic approaches to vaso-occlusive events in sickle cell disease. In addition, modulation of the channel by distinct receptor signals might provide opportunities for in vivo modification by specific inhibitors.
We thank Dr Nica Cappellini (Ospedale Maggore Policlinico, Milan, Italy) for generously providing liquid erythroid culture samples, and we thank Derek Larkin and Marie Zachlederova for their outstanding technical support.
Supported by National Institutes of Health grants P604L15157, DK50422, and RO3DK54866.
Submitted January 22, 2001; accepted September 4, 2001.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Alicia Rivera, Department of Laboratory Medicine, Bader 7, Children's Hospital Boston, 300 Longwood Ave, Boston, MA 02115; e-mail: rivera_a{at}a1.tch.harvard.edu.
1. Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol. 1998;61:49-54[Medline] [Order article via Infotrieve]. 2. Duits AJ, Schnog JB, Lard LR, Saleh AW, Rojer RA. Elevated IL-8 levels during sickle cell crisis. Eur J Haematol. 1998;61:302-305[Medline] [Order article via Infotrieve]. 3. Croizat H. Circulating cytokines in sickle cell patients during steady state. Br J Haematol. 1994;87:592-597[Medline] [Order article via Infotrieve].
4.
Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA.
Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis.
Blood.
1998;92:2551-2555
5.
Rybicki AC, Benjamin LJ.
Increased levels of endothelin-1 in plasma of sickle cell anemia patients [letter].
Blood.
1998;92:2594-2596 6. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia: a possible determinant of disease severity. N Engl J Med. 1980;302:992-995[Abstract].
7.
Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM.
Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion.
Blood.
1993;81:2137-2143 8. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol. 1996;81:96-98[CrossRef][Medline] [Order article via Infotrieve].
9.
Mozzarelli A, Hofrichter J, Eaton WA.
Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo.
Science.
1987;237:500-506 10. Bookchin RM, Balazs T, Landau LC. Determinants of red cell sickling: effects of varying pH and of increasing intracellular hemoglobin concentration by osmotic shrinkage. J Lab Clin Med. 1976;87:597-616[Medline] [Order article via Infotrieve]. 11. Apovo M, Beuzard Y, Galacteros F, Bachir D, Giraud F. The involvement of the Ca-dependent K channel and of the KCl co-transport in sickle cell dehydration during cyclic deoxygenation. Biochim Biophys Acta. 1994;1225:255-258[Medline] [Order article via Infotrieve]. 12. Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease [see comments]. J Clin Invest. 1996;97:1227-1234[Medline] [Order article via Infotrieve]. 13. Brugnara C, De Franceschi L, Alper SL. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives [see comments]. J Clin Invest. 1993;92:520-526.
14.
Li Q, Jungmann V, Kiyatkin A, Low PS.
Prostaglandin E2 stimulates a Ca2+-dependent K+ channel in human erythrocytes and alters cell volume and filterability.
J Biol Chem.
1996;271:18651-18656
15.
Rivera A, Rotter MA, Brugnara C.
Endothelins activate Ca(2+)-gated K(+) channels via endothelin B receptors in CD-1 mouse erythrocytes.
Am J Physiol.
1999;277:C746-C754
16.
de Winter RJ, Manten A, de Jong YP, Adams R, van Deventer SJ, Lie KI.
Interleukin 8 released after acute myocardial infarction is mainly bound to erythrocytes.
Heart.
1997;78:598-602
17.
Neote K, Mak JY, Kolakowski LF Jr, Schall TJ.
Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor.
Blood.
1994;84:44-52 18. Wolff D, Cecchi X, Spalvins A, Canessa M. Charybdotoxin blocks with high affinity the Ca-activated K+ channel of Hb A and Hb S red cells: individual differences in the number of channels. J Membr Biol. 1988;106:243-252[CrossRef][Medline] [Order article via Infotrieve]. 19. Goossens M, Kan YY. DNA analysis in the diagnosis of hemoglobin disorders. Methods Enzymol. 1981;76:805-817[Medline] [Order article via Infotrieve].
20.
Fibach E, Manor D, Oppenheim A, Rachmilewitz EA.
Proliferation and maturation of human erythroid progenitors in liquid culture.
Blood.
1989;73:100-103
21.
Bulbarelli A, Valentini A, DeSilvestris M, Cappellini MD, Borgese N.
An erythroid-specific transcript generates the soluble form of NADH-cytochrome b5 reductase in humans.
Blood.
1998;92:310-319
22.
Escobales N, Canessa M.
Ca2+-activated Na+ fluxes in human red cells. Amiloride sensitivity.
J Biol Chem.
1985;260:11914-11923
23.
Griendling KK, Tsuda T, Alexander RW.
Endothelin stimulates diacylglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells.
J Biol Chem.
1989;264:8237-8240 24. Ito Y, Murai Y, Ishibashi H, Onoue H, Akaike N. The prostaglandin E series modulates high-voltage-activated calcium channels probably through the EP3 receptor in rat paratracheal ganglia. Neuropharmacology. 2000;39:181-190[CrossRef][Medline] [Order article via Infotrieve]. 25. Sekiryu T, Fujiwara T. Effect of prostaglandin E2 on cytosolic calcium ion and morphology in cultured bovine retinal pigment epithelium. Fukushima J Med Sci. 1999;45:25-36[Medline] [Order article via Infotrieve].
26.
Neote K, Darbonne W, Ogez J, Horuk R, Schall TJ.
Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells.
J Biol Chem.
1993;268:12247-12249 27. Darbonne WC, Rice GC, Mohler MA, et al. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest. 1991;88:1362-1369.
28.
Szabo MC, Soo KS, Zlotnik A, Schall TJ.
Chemokine class differences in binding to the Duffy antigen-erythrocyte chemokine receptor.
J Biol Chem.
1995;270:25348-25351 29. Horuk R, Colby TJ, Darbonne WC, Schall TJ, Neote K. The human erythrocyte inflammatory peptide (chemokine) receptor: biochemical characterization, solubilization, and development of a binding assay for the soluble receptor. Biochemistry. 1993;32:5733-5738[CrossRef][Medline] [Order article via Infotrieve].
30.
Fathallah H, Sauvage M, Romero JR, Canessa M, Giraud F.
Effects of PKC alpha activation on Ca2+ pump and K(Ca) channel in deoxygenated sickle cells.
Am J Physiol.
1997;273:C1206-C1214 31. Gordge PC, Ryves WJ. Inhibitors of protein kinase C. Cell Signal. 1994;6:871-882[CrossRef][Medline] [Order article via Infotrieve]. 32. Oh SO, Ibe BO, Johnson C, Kurantsin-Mills J, Raj JU. Platelet-activating factor in plasma of patients with sickle cell disease in steady state. J Lab Clin Med. 1997;130:191-196[CrossRef][Medline] [Order article via Infotrieve].
33.
Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK.
Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants.
Science.
1975;189:561-563
34.
Liu QH, Williams DA, McManus C, et al.
HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation.
Proc Natl Acad Sci U S A.
2000;97:4832-4837 35. Araki S, Kawahara Y, Kariya K, Sunako M, Fukuzaki H, Takai Y. Stimulation of phospholipase C-mediated hydrolysis of phosphoinositides by endothelin in cultured rabbit aortic smooth muscle cells. Biochem Biophys Res Commun. 1989;159:1072-1079[CrossRef][Medline] [Order article via Infotrieve]. 36. Loffler BM, Lohrer W. Different endothelin receptor affinities in dog tissues. J Recept Res. 1991;11:293-298[Medline] [Order article via Infotrieve].
37.
Sugihara K, Sugihara T, Mohandas N, Hebbel RP.
Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells.
Blood.
1992;80:2634-2642 38. Salter KJ, Turner JL, Albarwani S, Clapp LH, Kozlowski RZ. Ca(2+)-activated Cl- and K+ channels and their modulation by endothelin-1 in rat pulmonary arterial smooth muscle cells. Exp Physiol. 1995;80:815-824[Abstract].
39.
Vandorpe DH, Shmukler BE, Jiang L, et al.
cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1: roles in regulatory volume decrease and erythroid differentiation.
J Biol Chem.
1998;273:21542-21553 40. Klaerke DA, Wiener H, Zeuthen T, Jorgensen PL. Regulation of Ca2+-activated K+ channel from rabbit distal colon epithelium by phosphorylation and dephosphorylation. J Membr Biol. 1996;151:11-18[CrossRef][Medline] [Order article via Infotrieve]. 41. Levitan IB. Modulation of ion channels by protein phosphorylation and dephosphorylation. Annu Rev Physiol. 1994;56:193-212[CrossRef][Medline] [Order article via Infotrieve]. 42. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest. 1995;96:1145-1151. 43. Wichterle H, Hanspal M, Palek J, Jarolim P. Combination of two mutant alpha spectrin alleles underlies a severe spherocytic hemolytic anemia. J Clin Invest. 1996;98:2300-2307[Medline] [Order article via Infotrieve]. 44. Jarolim P, Wichterle H, Hanspal M, Murray J, Rubin HL, Palek J. Beta spectrin PRAGUE: a truncated beta spectrin producing spectrin deficiency, defective spectrin heterodimer self-association and a phenotype of spherocytic elliptocytosis. Br J Haematol. 1995;91:502-510[Medline] [Order article via Infotrieve]. 45. Jarolim P, Rubin HL, Liu SC, et al. Duplication of 10 nucleotides in the erythroid band 3 (AE1) gene in a kindred with hereditary spherocytosis and band 3 protein deficiency (band 3PRAGUE). J Clin Invest. 1994;93:121-130.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. L. Krajewski, L. L. Hsu, and M. T. Gladwin The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H4 - H7. [Full Text] [PDF]
|
|
|
|
|
|
D. K. Kaul, X. Zhang, T. Dasgupta, and M. E. Fabry Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H39 - H47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rivera Reduced sickle erythrocyte dehydration in vivo by endothelin-1 receptor antagonists Am J Physiol Cell Physiol, September 1, 2007; 293(3): C960 - C966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yano, R. Mentaverri, D. Kanuparthi, S. Bandyopadhyay, A. Rivera, E. M. Brown, and N. Chattopadhyay Functional Expression of {beta}-Chemokine Receptors in Osteoblasts: Role of Regulated upon Activation, Normal T Cell Expressed and Secreted (RANTES) in Osteoblasts and Regulation of Its Secretion by Osteoblasts and Osteoclasts Endocrinology, May 1, 2005; 146(5): 2324 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Lang, D. S. Kempe, V. Tanneur, K. Eisele, B. A. Klarl, S. Myssina, V. Jendrossek, S. Ishii, T. Shimizu, M. Waidmann, et al. Stimulation of erythrocyte ceramide formation by platelet-activating factor J. Cell Sci., March 15, 2005; 118(6): 1233 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M C Muzyamba and J S Gibson Effect of 1-chloro-2,4-dinitrobenzene on K+ transport in normal and sickle human red blood cells J. Physiol., March 15, 2003; 547(3): 903 - 911. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
20°C for less than
2 months. A23187 ionophore was purchased from Calbiochem-Novabiochem
(La Jolla, CA). The iodinated ligand ET-1 and 86Rb were
purchased from Du Pont-New England Nuclear (Boston, MA). All other
reagents were purchased from Sigma Chemical (St Louis, MO).
P < .03.
and 
.